153 related articles for article (PubMed ID: 37321155)
1. Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
Jamieson A; McConechy MK; Lum A; Leung S; Thompson EF; Senz J; Talhouk A; Huntsman DG; Bashashati A; Gilks CB; McAlpine JN
Gynecol Oncol; 2023 Aug; 175():45-52. PubMed ID: 37321155
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier.
Huvila J; Orte K; Vainio P; Mettälä T; Joutsiniemi T; Hietanen S
Hum Pathol; 2021 May; 111():98-109. PubMed ID: 33662372
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
4. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
5. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
[TBL] [Abstract][Full Text] [Related]
6. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Rios-Doria E; Momeni-Boroujeni A; Friedman CF; Selenica P; Zhou Q; Wu M; Marra A; Leitao MM; Iasonos A; Alektiar KM; Sonoda Y; Makker V; Jewell E; Liu Y; Chi D; Zamarin D; Abu-Rustum NR; Aghajanian C; Mueller JJ; Ellenson LH; Weigelt B
Gynecol Oncol; 2023 Jul; 174():262-272. PubMed ID: 37245486
[TBL] [Abstract][Full Text] [Related]
7. Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis.
Rao Q; Liao J; Li Y; Zhang X; Xu G; Zhu C; Tian S; Chen Q; Zhou H; Zhang B
Cancer Med; 2023 Mar; 12(5):5409-5419. PubMed ID: 36341543
[TBL] [Abstract][Full Text] [Related]
8. Adoption of Universal Testing in Endometrial Cancers for Microsatellite Instability Using Next-Generation Sequencing.
Rodriguez IV; Strickland S; Wells D; Manhardt E; Konnick EQ; Garcia R; Swisher E; Kilgore M; Norquist B
JCO Precis Oncol; 2023 Sep; 7():e2300033. PubMed ID: 37856764
[TBL] [Abstract][Full Text] [Related]
9. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract][Full Text] [Related]
10. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers.
Gilson P; Levy J; Rouyer M; Demange J; Husson M; Bonnet C; Salleron J; Leroux A; Merlin JL; Harlé A
Sci Rep; 2020 Oct; 10(1):16386. PubMed ID: 33009475
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
13. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
14. Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
Stelloo E; Jansen AML; Osse EM; Nout RA; Creutzberg CL; Ruano D; Church DN; Morreau H; Smit VTHBM; van Wezel T; Bosse T
Ann Oncol; 2017 Jan; 28(1):96-102. PubMed ID: 27742654
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of next generation sequencing and immunohistochemistry on molecular classification of endometrial carcinoma].
Chen TT; Tao X; Liu TQ; Zhou XR
Zhonghua Bing Li Xue Za Zhi; 2023 Jun; 52(6):580-585. PubMed ID: 37263922
[No Abstract] [Full Text] [Related]
16. Investigation of discrepant mismatch repair immunohistochemistry and microsatellite instability polymerase chain reaction test results for gynecologic cancers using next-generation sequencing.
Smithgall MC; Remotti H; Hsiao SJ; Mansukhani M; Liu-Jarin X; Fernandes H
Hum Pathol; 2022 Jan; 119():41-50. PubMed ID: 34666078
[TBL] [Abstract][Full Text] [Related]
17. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
Abdulfatah E; Wakeling E; Sakr S; Al-Obaidy K; Bandyopadhyay S; Morris R; Feldman G; Ali-Fehmi R
Gynecol Oncol; 2019 Sep; 154(3):467-474. PubMed ID: 31248668
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study.
Gatius S; Velasco A; Varela M; Cuatrecasas M; Jares P; Setaffy L; Bonhomme B; Santon A; Lindemann K; Croce S; Davidson B; Lax S; Palacios J; Matias-Guiu X
Virchows Arch; 2022 May; 480(5):1031-1039. PubMed ID: 35124717
[TBL] [Abstract][Full Text] [Related]
20. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.
Kobayashi Y; Kitazono I; Akahane T; Yanazume S; Kamio M; Togami S; Nohara S; Sakamoto I; Yokoyama S; Tabata K; Kobayashi H; Tanimoto A
Pathol Oncol Res; 2021; 27():1610013. PubMed ID: 35002543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
